Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-1681
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors as Cancer Therapeutics

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Phosphatidylinositol 3-Kinase Mutations Identified in Human Cancer Are Oncogenic

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2005English

Treating Cancer With Phosphatidylinositol-3-Kinase Inhibitors: Increasing Efficacy and Overcoming Resistance

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2019English

Docking Study to Predict the Efficacy of Phosphatidylinositol 3-Kinase Α Inhibitors

ARO-THE SCIENTIFIC JOURNAL OF KOYA UNIVERSITY
2019English

Clinical Development of Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin Lymphoma

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2013English

Phosphatidylinositol-3-Kinase Pathway

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Gonadotropins Activate Proteolysis and Increase Invasion Through Protein Kinase a and Phosphatidylinositol 3-Kinase Pathways in Human Epithelial Ovarian Cancer Cells

Cancer Research
Cancer ResearchOncology
2006English

Triple Threat to Cancer: Rationale for Combining Oncolytic Viruses, MEK Inhibitors, and Immune Checkpoint Blockade

OncoImmunology
OncologyAllergyImmunology
2019English

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy